Clinical and molecular characteristics of ARID1A+ population
| Characteristics | ARID1A+ population, n = 25 | ARID1A– population, n = 245 |
|---|---|---|
| Gender | ||
| Female | 21 (84%) | 172 (70%) |
| Male | 4 (16%) | 73 (30%) |
| Ethnicity | ||
| Caucasic | 24 (96%) | 239 (97%) |
| Other | 1 (4%) | 6 (3%) |
| Age at diagnosis | ||
| Median, IQR | 59 (52–65) | 53 (45–61) |
| Histology | ||
| Gynecological | 15 (60%) | 83 (34%) |
| GI | 6 (24%) | 70 (29%) |
| Breast | 2 (8%) | 27 (11%) |
| Lung | 2 (8%) | 28 (11%) |
| Other | 0 | 37 (15%) |
| Number of metastatic sites | ||
| Median, IQR | 2 (1–3) | 2 (1–3) |
| Number of chemotherapy lines | ||
| Median, IQR | 2 (1–4) | 3 (2–4) |
| Concurrent medications | ||
| Median, IQR | 4 (3–5) | 3 (1–5) |
| CCI | ||
| Median, IQR | 10 (8–11) | 9 (8–10) |
| ECOG PS | ||
| 0 | 9 (36%) | 101 (41%) |
| 1 | 14 (56%) | 123 (50%) |
| 2 | 2 (8%) | 21 (9%) |
| Number of mutations | ||
| Median, IQR | 6 (5–16) | 4 (3–6) |
| TMB (mut/Mb) | ||
| Median, IQR | 20 (10.72–36) | 1.26 (0–6) |
| Number of VUS | ||
| Median, IQR | 12 (9–24) | 9 (6–12) |
| Microsatellite status | ||
| MSS | 12 (48%) | 176 (72%) |
| MSI-H | 8 (32%) | 3 (1%) |
| NA | 5 (20%) | 66 (27%) |
| Associated mutations | ||
| PIK3CA | 12 (48%) | 36 (15%) |
| TP53 | 12 (48%) | 155 (63%) |
| PTEN | 8 (32%) | 15 (6%) |
| CTNNB1 | 5 (20%) | 11 (5%) |
| MLL2 | 5 (20%) | 9 (4%) |
| ASXL1 | 4 (16%) | 3 (1%) |
IQR: inter-quartile range; GI: gastro-intestinal; CCI: Charlson comorbidity index; ECOG PS: Eastern Cooperative Oncology Group performance status; mut/Mb: mutations/megabase; VUS: variant of uncertain significance; MSS: microsatellite stability; MSI-H: microsatellite instability-high; NA: not applicable; TP53: tumor protein p53; CTNNB1: catenin beta 1; ASXL1: additional sex combs-like transcriptional regulator 1
